2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. PCSK9
  5. PCSK9 Inhibitor

PCSK9 Inhibitor

PCSK9 Inhibitors (66):

Cat. No. Product Name Effect Purity
  • HY-132591
    Inclisiran
    		Inhibitor
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-P99187
    Bococizumab
    		Inhibitor 99.80%
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
  • HY-120088A
    PF-06446846 hydrochloride
    		Inhibitor 99.85%
    PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
  • HY-132591A
    Inclisiran sodium
    		Inhibitor 98.10%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-P9928
    Alirocumab
    		Inhibitor
    Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.
  • HY-148626
    CVI-LM001
    		Inhibitor
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy.
  • HY-12402
    SBC-115076
    		Inhibitor 99.54%
    SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.
  • HY-P2276
    Pep2-8
    		Inhibitor 99.74%
    Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM.
  • HY-148673
    AZD0780
    		Inhibitor 99.97%
    PCSK9-IN-12 is a heteroaryl compound. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of ＜200 nM. PCSK9-IN-12 can be used for the research of cholesterol metabolism.
  • HY-12090
    Anacetrapib
    		Inhibitor 99.25%
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
  • HY-143221
    AS-Inclisiran sodium
    		Inhibitor
    AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-152221
    PCSK9-IN-10
    		Inhibitor 98.95%
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
  • HY-101354
    R-IMPP
    		Inhibitor 98.42%
    R-IMPP (PF-00932239) is an anti-secretagogue of PCSK9 (IC50=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.
  • HY-143219
    SS-Inclisiran sodium
    		Inhibitor 98.88%
    SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    		Inhibitor 99.00%
    Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia.
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    		Inhibitor
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-101832
    SBC-110736
    		Inhibitor 99.93%
    SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1.
  • HY-143220
    SS(no Galnac)-Inclisiran sodium
    		Inhibitor
    SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
  • HY-152223
    PCSK9-IN-11
    		Inhibitor 99.66%
    PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research.
  • HY-W510159
    5-O-Methylembelin
    		Inhibitor 98.84%
    5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, inducible degrader of the low-density lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2) mRNA expression.